Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment
NCT ID: NCT01421862
Last Updated: 2013-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
400 participants
OBSERVATIONAL
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies biomarkers in samples from adult patients with acute myeloid leukemia who failed standard-of-care treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
NCT00897182
Biomarkers in Samples of Bone Marrow From Patients With Acute Myeloid Leukemia
NCT01290107
Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
NCT01024127
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
NCT01385150
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia
NCT00898456
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Define a "non-response" signature that will help up-front identification of cases of intermediate-risk acute myeloid leukemia (AML) destined to fail existing standard-of-care therapy.
* Identify biological pathways in the "non-response" group that can provide targets for novel therapeutics.
OUTLINE: DNA and RNA extracted from cryopreserved bone marrow cells and/or blood cells are analyzed for mutations and gene expression signatures (genome-wide methylation, mRNA and miRNA expression, and single nucleotide polymorphism (SNP) analysis) by microarray assays.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA methylation analysis
RNA analysis
gene expression analysis
microarray analysis
mutation analysis
nucleic acid sequencing
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-response: AML with failure to achieve a complete remission (CR) after induction chemotherapy ("7 \& 3"-based therapy using cytatabine and/or daunorobicin hydrochloride (DNR) OR idarubicin and/or DNR
* Responders: continued complete remission (CCR) \> 2 years
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fred Hutchinson Cancer Research Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerry Radich, MD
Role: PRINCIPAL_INVESTIGATOR
Fred Hutchinson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CDR0000709269
Identifier Type: REGISTRY
Identifier Source: secondary_id
FHCRC-9140
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.